On-target, off-leukemia activity of CAR iNKT cells was confirmed by a significant reduction in the frequency of CD19+ B cells in the PB at day 1 and day 3 after CAR-iNKT cell injection, compared with controls (Figure 7C; supplemental Figure 8B). The gene discussed is CD19; the disease is leukemia.